# Sinovac Research and Development Co., Ltd. trials: 22 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 22 trials with Sinovac Research and Development Co., Ltd. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Sinovac Research and Development Co., Ltd.: 22 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/sinovac-research-and-development-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 22
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 22 newest of 22, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| December 27, 2023 | NCT06183216 | A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine | Sinovac Research and Development Co., Ltd. | Phase 1 | Completed | Pneumococcal Infectious Disease | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06183216) |
| May 19, 2022 | NCT05381350 | Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cell), Inactivated (Omicron Variant) in Healthy People Aged 18... | Sinovac Research and Development Co., Ltd. | Phase 3 | Completed | COVID-19 | 1,750 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05381350) |
| May 10, 2022 | NCT05367895 | Effectiveness of Inactivated COVID-19 Vaccine of the First Booster Dose | Sinovac Research and Development Co., Ltd. | Observational | Unknown | COVID-19 | 14,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05367895) |
| February 24, 2022 | NCT05254236 | Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated Vaccine in Healthy Adults in in Hong... | Sinovac Research and Development Co., Ltd. | Phase 2 | Withdrawn | COVID-19 | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05254236) |
| January 20, 2022 | NCT05198336 | Immunogenicity of an Inactivated COVID-19 Vaccine | Sinovac Research and Development Co., Ltd. | Phase 4 | Completed | COVID-19 | 395 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05198336) |
| December 21, 2021 | NCT05165732 | Safety and Immunogenicity Study of Booster Vaccination With COVID-19 Vaccine (Vero Cell),Inactivated From Different Manufactures for... | Sinovac Research and Development Co., Ltd. | Phase 4 | Suspended | COVID-19 | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05165732) |
| December 14, 2021 | NCT05156632 | Efficacy,Immunogenicity and Safety of COVID-19 Vaccine , Inactivated Booster Dose in Adults Aged 18 Years and Above | Sinovac Research and Development Co., Ltd. | Phase 3 | Withdrawn | COVID-19 | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05156632) |
| December 9, 2021 | NCT05150496 | Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults... | Sinovac Research and Development Co., Ltd. | Phase 2 | Suspended | COVID-19 | 640 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05150496) |
| November 30, 2021 | NCT05137418 | Safety and Immunogenicity of COVID-19 Vaccine, Inactivated in Healthy Population Aged From 3 to 11 Years | Sinovac Research and Development Co., Ltd. | Phase 3 | Completed | COVID-19 | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05137418) |
| November 9, 2021 | NCT05112913 | Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine Between Different Workshops in Healthy Children Aged 3-17 Years | Sinovac Research and Development Co., Ltd. | Phase 4 | Unknown | COVID-19 | 2,520 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05112913) |
| October 1, 2021 | NCT05065177 | Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants | Sinovac Research and Development Co., Ltd. | Phase 3 | Completed | Mumps | 1,140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05065177) |
| August 6, 2021 | NCT04993365 | Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell) | Sinovac Research and Development Co., Ltd. | Phase 4 | Completed | COVID-19 | 520 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04993365) |
| August 5, 2021 | NCT04992260 | Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Children and Adolescents | Sinovac Research and Development Co., Ltd. | Phase 3 | Completed | COVID-19 | 11,349 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04992260) |
| July 23, 2021 | NCT04974164 | Effectiveness of COVID-19 Vaccine for Prevention of COVID-19 in the Dominican Republic | Sinovac Research and Development Co., Ltd. | Observational | Completed | COVID-19 | 1,400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04974164) |
| July 14, 2021 | NCT04962308 | Clinical Trial of Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults | Sinovac Research and Development Co., Ltd. | Phase 4 | Unknown | COVID-19 | 1,400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04962308) |
| July 7, 2021 | NCT04953325 | Immunogenicity and Safety of an Inactivated COVID-19 Vaccine | Sinovac Research and Development Co., Ltd. | Phase 4 | Completed | COVID-19 | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04953325) |
| June 3, 2021 | NCT04911790 | Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults | Sinovac Research and Development Co., Ltd. | Phase 4 | Completed | COVID-19 | 131,650 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04911790) |
| May 20, 2021 | NCT04894227 | Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults | Sinovac Research and Development Co., Ltd. | Phase 4 | Completed | COVID-19 | 1,080 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04894227) |
| March 17, 2021 | NCT04801888 | Study on Combined Vaccination With SARS-CoV-2 Inactivated Vaccine and Quadrivalent Influenza Vaccine | Sinovac Research and Development Co., Ltd. | Phase 4 | Completed | COVID-19, Influenza | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04801888) |
| November 5, 2020 | NCT04617483 | Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly... | Sinovac Research and Development Co., Ltd. | Phase 3 | Completed | Covid19 | 1,040 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04617483) |
| September 16, 2020 | NCT04551547 | Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of COVID-19 | Sinovac Research and Development Co., Ltd. | Phase 1/2 | Completed | COVID-19 | 552 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04551547) |
| April 20, 2020 | NCT04352608 | Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19) | Sinovac Research and Development Co., Ltd. | Phase 1/2 | Completed | COVID-19 | 744 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04352608) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 1 |
| Phase 1/2 | 2 |
| Phase 2 | 2 |
| Phase 3 | 6 |
| Phase 4 | 9 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 15 |
| Unknown | 3 |
| Withdrawn | 2 |
| Suspended | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| COVID-19 | 20 |
| Pneumococcal Infections | 1 |
| Influenza, Human | 1 |
| Mumps | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Tiki bars in the United States](https://specstream.ai/data/businesses/tiki-bars/united-states)
- [Well drilling companies in the United States](https://specstream.ai/data/businesses/well-drilling-companies/united-states)
- [Asian restaurants in the United States](https://specstream.ai/data/businesses/asian-restaurants/united-states)
- [Bathroom remodelers in the United States](https://specstream.ai/data/businesses/bathroom-remodelers/united-states)
- [Certification bodies in the United States](https://specstream.ai/data/businesses/certification-bodies/united-states)
- [Day care centers in the United States](https://specstream.ai/data/businesses/day-care-centers/united-states)
